Ticagrelor NDC 71610-958

NDC codes

FDA NDC Directory

Product NDC (as listed)71610-958Labeler and product segments. Claims need a package NDC.

Product NDC at billing width71610-0958Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
71610-958-41	71610095841	5400 TABLET in 1 BOTTLE (71610-958-41)Marketed from Oct 22, 2025
71610-958-42	71610095842	1800 TABLET in 1 BOTTLE (71610-958-42)Marketed from Nov 21, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Ticagrelor
Generic name (nonproprietary): ticagrelor
Active ingredients: Ticagrelor — 90 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Aphena Pharma Solutions - Tennessee, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 208584
Marketing start: May 1, 2025
Listing expires: Dec 31, 2026
Other FDA classes: Cytochrome P450 3A4 Inhibitors (Mechanism)Decreased Platelet Aggregation (Physiologic effect)P-Glycoprotein Inhibitors (Mechanism)P2Y12 Receptor Antagonists (Mechanism)
Identifiers: Product ID 71610-958_445e4a36-0326-75ec-e063-6294a90aaa26SPL ID 445e4a36-0326-75ec-e063-6294a90aaa26SPL set ID 41c5d35c-91de-a8a4-e063-6394a90ac5ffRxCUI 1116635UNII GLH0314RVC
Pharmacologic class: P2Y12 Platelet Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N471610095841 followed by a unit qualifier and the quantity

Package 71610-0958-41. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 24, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Ticagrelor tablets are a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. Ticagrelor tablets also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of ticagrelor tablets were established in a population with type 2 diabetes mellitus (T2DM). (1.2) to reduc…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 208584

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 208584
Product	Strength	Form · route	Labeler	Product NDC
Ticagrelor	Ticagrelor 60 mg/1	TabletOral	Apotex Corp.	60505-4453
Ticagrelor	Ticagrelor 90 mg/1	TabletOral	Apotex Corp.	60505-4452
Ticagrelor	Ticagrelor 90 mg/1	TabletOral	Golden State Medical Supply, Inc.	51407-861